Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AGS62P1 |
Synonyms | |
Therapy Description |
AGS62P1 is a human anti-FLT3 antibody in conjugation with a microtubule disrupting agent, which may have anti-tumor activity (Blood 2015 126(23):3806, PMID: 29757653). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AGS62P1 | FLT3 Antibody 5 | AGS62P1 is a human anti-FLT3 antibody in conjugation with a microtubule disrupting agent, which may have anti-tumor activity (Blood 2015 126(23):3806, PMID: 29757653). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 positive | acute myeloid leukemia | predicted - sensitive | AGS62P1 | Preclinical - Patient cell culture | Actionable | In a preclinical study, AGS62P1 inhibited growth of FLT3-positive acute myeloid leukemia cell lines in culture, and led to tumor growth inhibition and regression in patient-derived xenograft (PDX) models (Blood 2015 126(23):3806). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02864290 | Phase I | AGS62P1 | A Study to Evaluate Escalating Doses of AGS62P1 Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML) | Terminated | USA | CAN | 0 |